Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: An option for monitoring response to breast cancer related therapies

Breast Cancer Research and Treatment

Volumn 115, Issue 3, 2009, Pages 581-590

  Tewes, Mitra ^a   Aktas, Bahriye ^a   Welt, Anja ^a   Mueller, Siemke ^b   Hauch, Siegfried ^c   Kimmig, Rainer ^a   Kasimir Bauer, Sabine ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Marienkrankenhaus GmbH   (Germany)

^c AdnaGen AG   (Germany)

Author keywords

Circulating tumor cells; Metastatic breast cancer; Molecular profiling; Therapy monitoring

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; FLUOROURACIL; MUCIN 1; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR CELL;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 67349253810     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0143-x     Document Type: Article

References (40)

1. A Goldhirsch JH Glick RD Gelber 2005 Meeting highlights: international expert consensus conference on the primary therapy of early breast cancer Ann Oncol 16 1569 1583 (Pubitemid 41511089)
2. S Braun F Hepp HL Sommer 1999 Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease Int J Cancer 84 1 5 (Pubitemid 29059099)
3. K Pantel G Schlimok S Braun 1993 Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells J Natl Cancer Inst 85 1419 24
4. S Meng D Tripathy EP Frenkel 2004 Circulating tumor cells in patients with breast cancer dormancy Clin Cancer Res 10 8152 8162 (Pubitemid 40053373)
5. S Kasimir-Bauer S Mayer P Bojko 2001 Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy Clin Cancer Res 7 1582 1588
6. S Braun C Kentenich W Janni 2000 Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients J Clin Oncol 18 80 86 (Pubitemid 30036339)
7. G Wiedswang E Borgen C Schirmer 2006 Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer Int J Cancer 118 2013 2019
8. S Braun FD Vogl B Naume 2005 A pooled analysis of bone marrow micrometastasis in breast cancer N Engl J Med 53 793 802 (Pubitemid 41215488)
9. A Stathopoulou I Vlachonikolis D Mavroudis 2002 Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance J Clin Oncol 20 3404 3412
10. A Giatromanolaki MI Koukourakis S Kakolyris 2004 Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse Int J Cancer 108 620 627 (Pubitemid 38036666)
11. J-J Gaforio M-J Serrano P Sanchez-Rovira 2003 Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis Int J Cancer 107 984 990 (Pubitemid 37429841)
12. T Jotsuka Y Okumura S Nakano 2004 Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer Surgery 135 419 426 (Pubitemid 38453497)
13. J-Y Pierga Ch Bonneton A Vincent-Salomon 2004 Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients Clin Cancer Res 10 1392 1400 (Pubitemid 38365234)
14. IH Benoy H Elst M Philips 2006 Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer Br J Cancer 94 672 680 (Pubitemid 43361898)
15. G Mehes A Witt E Kubista 2001 Circulating breast cancer cells are frequently apoptotic Am J Pathol 159 17 20 (Pubitemid 33704186)
16. M Cristofanilli GT Budd MJ Ellis 2004 Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 781 791 (Pubitemid 39095313)
17. M Cristofanilli KR Broglio V Guarneri 2007 Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden Clin Breast Cancer 7 6 471 479 (Pubitemid 46424284)
18. DF Hayes TM Walker B Singh 2002 Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer Int J Oncol 21 1111 1117
19. AJ Bosma B Weigelt AC Lambrechts 2002 Detection of circulating breast tumor cells by differential expression of marker genes Clin Cancer Res 8 1871 1877 (Pubitemid 34633748)
20. AE Ring L Zabaglo MG Ormerod 2005 Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques Br J Cancer 92 906 912 (Pubitemid 40462638)
21. MK Baker K Mikhitarian W Osta 2003 Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology Clin Cancer Res 9 4865 4871 (Pubitemid 37323291)
22. S Hauch S Zimmermann S Lankiewicz 2007 The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients Anticancer Res (Greece) 27 1337 1341 (Pubitemid 46807280)
23. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V (2003) Invasive breast carcinoma. In: Tavassoli FA, Devilee P (eds) World health organization classification of tumours. tumours of the breast and female genital organs. IARC Press, Lyon
24. Sobin LH, Wittekind C (2002) International union against cancer. TNM classification of malignant tumours, 6th edn. Wiley, New York
25. P Lal PA Salazar CA Hudis 2004 HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2, 279 cases and comparison of dual-color and single-color scoring Am J Clin Pathol 121 631 636 (Pubitemid 38533994)
26. U Demel GP Tilz Z Foeldes-Papp 2004 Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay J Exp Clin Cancer Res 23 465 468 (Pubitemid 39490631)
27. V Zieglschmid C Hollmann B Gutierrez 2005 Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells Anticancer Res 25 1803 1810 (Pubitemid 40896806)
28. S Lankiewicz BG Rivero O Bocher 2006 Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment Mol Biotechnol (USA) 34 1 15 27 (Pubitemid 44337216)
29. S Braun G Schlimok I Heumos 2001 ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients Cancer Res 61 1890 1895 (Pubitemid 32692004)
30. AJ Vincent-Salomon C Couturier X Nos 2004 HER2 gene status assessment in micrometastatic cells in bone marrow (BM) of breast cancer patients by fluorescence in situ hybridization J Clin Oncol 22 9520
31. S Becker G Becker-Pergola T Fehm 2005 HER2 expression on disseminated tumor cells from bone marrow of breast cancer patients Anticancer Res 25 2171 2176
32. EF Solomayer S Becker G Pergola-Becker 2006 Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients Breast Cancer Res Treat 98 2 179 184 (Pubitemid 44050767)
33. A Italiano MC Saint-Paul FX Caroli-Bosc 2005 Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications Ann Oncol 16 9 1503 1507 (Pubitemid 41222423)
34. Reuben JM, Lee BN, Li C et al. (2007) Genomic of circulating tumor cells in metastatic breast cancer. J Clin Oncol ASCO annual meeting proceedings part I 25(18S):1002 (June 20 Supplement)
35. T Fehm L Morrison H Saboorian 2002 Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors Breast Cancer Res Treat 75 3 227 239
36. K Pachmann C Oumar A Kavallaris 2008 Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse J Clin Oncol 26 8 1208 1215
37. RC Bast P Ravdin DF Hayes 2001 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 6 1865 1878 (Pubitemid 32230890)
38. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12(21):6403-6409 (Pubitemid 44799711)
39. DF Hayes M Cristofanilli GT Budd 2006 Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival Clin Cancer Res 12 14 Pt 1 4218 4224
40. LM McShane DG Altman W Sauerbrei 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 2 229 235 (Pubitemid 44631925)